■ 华润江中药业股份有限公司关于第二期限制性股票激励计划预留授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 根据中国证券监督管理委员会《上市公司股权激励管理办法》、上海证券交易所、中国证券登记结算有 限责任公司上海分公司的有关规定，华润江中药业股份有限公司（以下简称"公司"）已完成公司第二期 限制性股票激励计划（以下简称"本激励计划"）的预留授予登记工作，有关具体情况如下： 一、本激励计划预留授予情况 公司于2026年2月3日召开第十届董事会第十二次会议，审议通过了《关于向公司第二期限制性股票激励 计划激励对象授予预留限制性股票的议案》，确定本激励计划的预留授予日为2026年2月3日，向符合条 件的28名激励对象授予66万股限制性股票，授予价格为13.70元/股。公司薪酬与考核委员会已事前审议 通过该议案并出具了核查意见。 本次申请授予登记的相关情况与经公司2024年年度股东大会审议通过的公司第二期限制性股票激励计划 的方案及经公司第十届董事会第十二次会议审议通过的预留授予情况相符。 综上， ...

证券代码：600750 证券简称：华润江中 公告编号：2026-007 华润江中药业股份有限公司 关于第二期限制性股票激励计划预留授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 根据中国证券监督管理委员会《上市公司股权激励管理办法》、上海证券交 易所、中国证券登记结算有限责任公司上海分公司的有关规定，华润江中药业股 份有限公司（以下简称"公司"）已完成公司第二期限制性股票激励计划（以下 简称"本激励计划"）的预留授予登记工作，有关具体情况如下： 一、本激励计划预留授予情况 公司于 2026 年 2 月 3 日召开第十届董事会第十二次会议，审议通过了《关 于向公司第二期限制性股票激励计划激励对象授予预留限制性股票的议案》，确 定本激励计划的预留授予日为 2026 年 2 月 3 日，向符合条件的 28 名激励对象授 予 66 万股限制性股票，授予价格为 13.70 元/股。公司薪酬与考核委员会已事前 审议通过该议案并出具了核查意见。 本次申请授予登记的相关情况与经公司 2024 年年度股东大会 ...

Core Insights - The Chinese nutrition and health industry is experiencing a surge in IPO activities, indicating a shift from local operations to global expansion and a focus on scientific validation [4][5]. IPO Developments - In 2025, several companies in the nutrition and health sector are set to go public, covering the entire supply chain from raw materials to manufacturing and branding [4]. - Dongpeng Beverage plans to list on the Hong Kong Stock Exchange in early 2026, aiming to raise over HKD 10.1 billion, marking the largest IPO in the non-alcoholic beverage sector in Hong Kong history [4]. - Xianle Health is advancing its H-share listing while optimizing its global CDMO platform by divesting non-core assets [4]. - Ruoyuchen has submitted its application to the Hong Kong Stock Exchange, focusing on its proprietary brand FineNutri to transition from a service provider to a brand owner [4]. - Other companies like Jiyuan Group and Hengmei Health are also pursuing listings to enhance their production capacities and market presence [4][5]. Regulatory Updates - The National Market Supervision Administration has released several guidelines and regulations affecting the health and nutrition sector, including the review of special medical formula food production licenses and the management of live-streaming e-commerce [6][7]. - New regulations have been introduced to ensure compliance in the marketing of health products, including a ban on certain food sales in live-streaming environments [6]. Market Trends - There is a notable increase in demand for health supplements, with sales of ginseng and other tonic products rising by 55% year-on-year during the New Year holiday [17]. - The import of medical and health products has also seen significant growth, with a 70.4% increase in imports in Hubei province in 2025 [17]. Industry Insights - The current wave of capital influx is not merely for financing but signals a critical transition in the industry towards scientific validation and global operations [4]. - Companies with genuine research capabilities, compliant product systems, and international perspectives are expected to gain a competitive edge in high-quality development [4].

Group 1: Development Goals and Framework - The State-owned Assets Supervision and Administration Commission (SASAC) has set the annual development goals centered on "two guarantees and two strives" for 2026, marking a shift towards quality and efficiency in state-owned enterprises (SOEs) [4] - The total assets of central enterprises have surpassed 95 trillion yuan, with R&D investment exceeding 1 trillion yuan for four consecutive years, indicating a focus on quality-driven growth [8] - The framework aims to guide state capital towards strategic security, public welfare, and emerging industries, providing a clear action plan for reform and development [4] Group 2: Industry Integration and Collaboration - In 2025, the restructuring of central enterprises will follow a dual-track approach, focusing on strategic formation of new central enterprises and multi-field professional integration [13] - The establishment of new central enterprises, such as China Yajiang Group and China Chang'an Automobile Group, aims to serve national macro strategies and enhance industry collaboration [14] - A total of 17 units signed agreements in key areas like artificial intelligence and new materials, creating a multi-party collaborative model involving central enterprises, private enterprises, and local governments [16] Group 3: Capital Investment and Fund Management - The total scale of the China Chengtong fund system reached 710 billion yuan, with 97.99% allocated to strategic emerging industries, demonstrating a strong focus on high-tech sectors [18] - The National Investment Group manages 61 funds with a total scale of 345.1 billion yuan, having invested in 1,249 projects and facilitated 293 companies going public [20] - The investment strategy emphasizes long-term support for innovative enterprises, with over two-thirds of funds directed towards private enterprises [20] Group 4: Resource Integration and Security - Central enterprises are undergoing intensive integration in key mineral sectors, such as iron ore and rare earths, to enhance resource control and pricing power [24] - The integration aims to create a closed-loop industry chain, improving domestic supply security and reducing reliance on imports [25] - This strategic move is seen as a vital step in ensuring national resource security and enhancing the global influence of China's mineral resources [24]

Investment Rating - The report maintains a "Buy" rating for key companies in the pharmaceutical sector, including Innovent Biologics, Efang Biologics, Tianshili, WuXi AppTec, and Mindray Medical [4][28]. Core Insights - The policy-driven upgrade of traditional Chinese medicine (TCM) industry is expected to enhance industry concentration in the medium to long term, benefiting companies with strong quality control and innovative capabilities [2][24]. - The implementation plan for high-quality development of the TCM industry aims to establish a collaborative development system by 2030, focusing on raw material supply, innovation, production quality control, and internationalization [2][23]. - The investment strategy emphasizes the importance of clinical value in the pharmaceutical sector, recommending a focus on innovative drugs and high-end medical devices [3][26]. Summary by Sections Market Review - The A-share pharmaceutical index rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [1][16]. - The Hong Kong Hang Seng Medical Health Index fell by 1.41%, but still outperformed the Hang Seng Index by 1.65 percentage points [1][16]. Policy Insights - The Ministry of Industry and Information Technology and other departments issued a plan to enhance the TCM industry, which includes fostering leading enterprises and establishing high-standard raw material production bases [2][24]. - The plan emphasizes digitalization and sustainability, aiming to raise compliance standards and accelerate the exit of smaller companies from the market [2][25]. Company Updates - Recent clinical progress includes the NDA submission for HRS-9531 by Heng Rui Medicine and the initiation of clinical trials for various drugs by other companies [1][31][32]. - Key companies such as Yunnan Baiyao, Baiyunshan, and Taiji Group are highlighted for their strong positions in raw material supply [2][25]. Financial Forecasts - The report provides earnings per share (EPS) forecasts for key companies, with Innovent Biologics projected to have an EPS of 0.49 in 2025 and WuXi AppTec expected to reach an EPS of 5.07 in the same year [4][28]. - The pharmaceutical manufacturing industry reported a revenue decline of 1.2% year-on-year for 2025, with total revenue reaching 2,487 billion yuan [51].

格隆汇2月6日丨华润江中(600750.SH)涨1.26%，报25.800元，股价创历史新高，总市值163.82亿元。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600750 证券简称：华润江中 公告编号：2026-005 华润江中药业股份有限公司 第十届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 华润江中药业股份有限公司（以下简称"公司"或"华润江中"）第十届董事会第十二次会议于2026年2月3 日在公司会议室以现场结合视频方式召开，会议通知于2026年1月29日以书面形式发出，会议应到董事 11人，实到董事11人。公司部分高级管理人员列席。本次会议召集召开符合《公司法》和《公司章程》 的有关规定。 会议由公司董事长刘为权先生主持，经与会董事充分研究和讨论，审议通过以下议案： 一、关于向公司第二期限制性股票激励计划激励对象授予预留限制性股票的议案 表决情况：11票同意，0票反对，0票弃权，通过本议案。 根据《上市公司股权激励管理办法》、公司《第二期限制性股票激励计划》的有关规定，以及公司2024 年年度股东大会的授权，公司第二期限制性股票激励计划规定的预留授予条件已经成就，同意以2026 ...

华润江中药业股份有限公司 第二期限制性股票激励计划预留授予激励对象名单（授予日） | 一、总体情况 | | --- | 注：上述合计数与各明细数直接相加之和在尾数上如有差异，是由于四舍五入所 造成。 | 17 | 卢蕾 | 中层、科研骨干、核心骨干 | | --- | --- | --- | | 18 | 钟地长 | 中层、科研骨干、核心骨干 | | 19 | 冷胡峰 | 中层、科研骨干、核心骨干 | | 20 | 彭科 | 中层、科研骨干、核心骨干 | | 21 | 曾一心 | 中层、科研骨干、核心骨干 | | 22 | 贺小平 | 中层、科研骨干、核心骨干 | | 23 | 邱红梅 | 中层、科研骨干、核心骨干 | | 24 | 肖春花 | 中层、科研骨干、核心骨干 | | 25 | 黎平 | 中层、科研骨干、核心骨干 | | 26 | 李路远 | 中层、科研骨干、核心骨干 | | 序号 | 姓名 | 分类 | | --- | --- | --- | | 1 | 徐伟 | 中层、科研骨干、核心骨干 | | 2 | 彭松林 | 中层、科研骨干、核心骨干 | | 3 | 杨劼 | 中层、科研骨干、核心骨干 | ...

证券代码：600750 证券简称：华润江中 公告编号：2026-006 ●限制性股票预留授予数量：66万股 ●限制性股票预留授予价格：13.70元/股 华润江中药业股份有限公司（以下简称"公司"）于 2026 年 2 月 3 日召开第十 届董事会第十二次会议，审议通过了《关于向公司第二期限制性股票激励计划激励对 象授予预留限制性股票的议案》，现将《第二期限制性股票激励计划》（以下简称"本 次激励计划"）授予有关事项进行如下说明： 一、本次激励计划权益授予情况 （一）已履行的决策程序和信息披露情况 华润江中药业股份有限公司 关于向公司第二期限制性股票激励计划激励对象 授予预留限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●限制性股票预留授予日：2026年2月3日 1、2024 年 1 月 2 日，公司召开第九届董事会第十七次会议和第九届监事会第十 四次会议，审议通过了《关于公司第二期限制性股票激励计划（草案）》及其摘要等 相关议案。 2、2024 年 12 月 31 日，公司召开第十届董 ...

国浩律师（上海）事务所 关 于 华润江中药业股份有限公司 第二期限制性股票激励计划 预留部分授予事项 之 法律意见书 第二期限制性股票激励计划预留部分授予事项之 法律意见书 致：华润江中药业股份有限公司 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China T. +86 21 52341668 F. +86 21 52341670 E. grandallsh@grandall.com.cn W. www.grandall.com.cn 2026 年 2 月 国浩律师（上海）事务所（以下简称"本所"）接受华润江中药业股份有限公 司（以下简称"华润江中"或"公司"）的委托，作为其实施第二期限制性股票激 励计划（以下简称"本次激励计划"）的特聘专项法律顾问。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办 法》（以下简称"《管理办法》"）等 ...